A supplemental biologics license application has been submitted to the FDA for the full regulatory approval of blinatumomab as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.
A recent study published in the Journal of Clinical Oncology has found that Philadelphia chromosome-like acute lymphoblastic leukemia (ALL) accounts for over 20% of all adult patients with ALL and is correlated with poor outcomes.
Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.
A study presented at the 2017 ASH Annual Meeting identified potential biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia.
At 29 months’ follow-up, frontline ibrutinib reduced the risk of of progression or death by 88% versus chlorambucil in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to the latest findings from the phase III RESONATE-2 trial.
Jeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.
Patients with lymphoma who are treated with brentuximab vedotin (BV) often experience peripheral neuropathy as an adverse event and potentially dose-limiting toxicity. A novel study has shown that, despite the prevalence of this toxicity, these patients report that the better outcomes yielded from treatment with BV outweigh the risk of neuropathy.
Peter Martin, MD, discusses the efficacy of a combination regimen of ibrutinib and palbociclib in the treatment of patients with mantle cell lymphoma.
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of lenalidomide as a maintenance therapy following autologous stem cell transplant for patients with newly diagnosed multiple myeloma.
Jennifer A. Woyach, MD, discusses the preliminary results of an ongoing phase II trial of MOR208 combination regimens in chronic lymphocytic leukemia.